Nat Med. 2023;29(11):2919-2928. doi:10.1038/s41591-023-02603-1

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Stephen A Harrison, Rebecca Taub, Guy W Neff, K Jean Lucas, Dominic Labriola, Sam E Moussa, Naim Alkhouri, Mustafa R Bashir

N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E Moussa, Guy W Neff, Mary E Rinella, Quentin M Anstee, Manal F Abdelmalek, Zobair Younossi, Seth J Baum, Sven Francque, Michael R Charlton, Philip N Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M Pericàs, Rashmee Patil, Arun J Sanyal, Mazen Noureddin, Meena B Bansal, Naim Alkhouri, Laurent Castera, Madhavi Rudraraju, Vlad Ratziu 1; MAESTRO-NASH Investigators

Aliment Pharmacol Ther. 2024;59(1):51-63. doi:10.1111/apt.17734

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, Mazen Noureddin, Arun J Sanyal, Jörn M Schattenberg, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley, Zobair M Younossi, Rohit Loomba